SST signs partnership agreement with an OTC firm for US commercial rights to topical Ibuprofen
The partner has received an exclusive option to obtain U.S. commercial rights to SST’s topical ibuprofen (SST-0225) upon its approval by the U.S. FDA. SST-0225 is a patented
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.